GTBP
GT Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.69
−4.84%Next report
Analyst consensus
- Next report date
- Nov 13, 2026
- EPS estimate
- -$2.50
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- -$0.12
- EPS estimate
- -$0.08
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -46.7%
- Revenue beats (12Q)
- —
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | -$0.08 | -$0.12 | Miss -50.00% | — |
| May 15, 2026 | -$0.08 | -$0.11 | Miss -37.50% | — |
| Nov 14, 2025 | -$0.38 | -$0.83 | Miss -118.42% | — |
| Aug 14, 2025 | -$0.68 | -$0.55 | Beat 19.12% | — |
| May 15, 2025 | -$0.64 | -$0.76 | Miss -18.75% | — |
| Feb 21, 2025 | -$1.55 | -$1.66 | Miss -7.10% | — |
| Nov 14, 2024 | -$2.70 | -$1.53 | Beat 43.33% | — |
| Aug 14, 2024 | -$2.70 | -$2.24 | Beat 17.04% | — |
| May 15, 2024 | -$2.70 | -$2.12 | Beat 21.48% | — |
| Nov 1, 2023 | -$3.00 | -$1.80 | Beat 40.00% | — |
| May 15, 2023 | -$4.80 | -$2.40 | Beat 50.00% | — |
| Oct 31, 2022 | -$3.30 | -$6.61 | Miss -100.30% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 13, 2026